CLVS Clovis Oncology Inc.

-0.87  -4%
Previous Close 21.63
Open 21
Price To Book 4.69
Market Cap 1094297529
Shares 52,711,827
Volume 4,738,331
Short Ratio
Av. Daily Volume 3,382,789

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrollment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Mutant EGFR T790M-positive lung cancer
Development discontinued
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 initial data presented at ESMO - 44% ORR.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 ongoing.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
HR+ Her2- metastatic breast cancer